Six-year follow-up of pancreatic β cell function in adults with latent autoimmune diabetes

World Journal of Gastroenterology

Volumn 11, Issue 19, 2005, Pages 2900-2905

  Yang, Lin ^a   Zhou, Zhi Guang ^a   Huang, Gan ^a   Ouyang, Ling Li ^b   Li, Xia ^a   Yan, Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Glutamic acid decarboxylase antibody; Islet cell function; Latent autoimmune diabetes in adults; Type 2 diabetes

Indexed keywords

BIGUANIDE; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; SULFONYLUREA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; PHENOTYPE; PREDICTION; PROGNOSIS; RADIOASSAY; RADIOIMMUNOASSAY; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 20344363171     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i19.2900     Document Type: Article

References (31)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-362
2. Hagopian WA, Karlsen AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, Petersen JS, Boel E, Dyrberg T, Lernmark A. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993; 91: 368-374
3. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902-910
4. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157
5. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18: 1557-1565
6. Goetz FC, Roel J, Jacobs DR Jr, Barbosa J, Hannan P, Palmer J, Hagopian W. Declining beta-cell function in type 2 diabetes: 5-year follow-up and immunologic studies of the population of Wadena, MN. Metabolism 2002; 51: 144-148
7. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51: 1754-1762
8. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86: 3032-3038
9. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11: 299-303
10. Zhou ZG, Wu HW. Diagnosis and treatment of latent autoimmune diabetes in adults (LADA). Zhonghua Neifenmi Daixie Zazhi 1998; 14: 1-2
11. Petersen JS, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, Hoier-Madsen M, Boel E, Michelsen BK, Dyrberg T. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994; 43: 459-467
12. 65 antigen. Zhonghua Heyixue Zazhi 2003; 23: 82-86
13. Falorni A, Ortqvist E, Persson B, Lernmark A. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 1995; 186: 89-99
14. Woo W, LaGasse JM, Zhou Z, Patel R, Palmer JP, Campus H, Hagopian WA. A novel high-throughput method for accurate, rapid, and economical measurement of multiple type 1 diabetes autoantibodies. J Immunol Methods 2000; 244: 91-103
15. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-1293
16. No authors listed. U.K. prospective diabetes study 16. Overview of 6 years, therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258
17. Gottsater A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA. Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes. Diabetes Res Clin Pract 1995; 27: 133-140
18. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, Lan MS, Notkins AL, Heine RJ, Scherbaum WA. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897
19. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J. Prognostic factors for the course of β cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000; 85: 4619-4623
20. Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G. Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 2001; 33: 115-120
21. Rattarasarn C, Diosdado MA. Clinical characteristics, and time course of pancreatic beta-cell function and glutamic acid decarboxylase antibodies in Thai patients with adult-onset Type 1 diabetes: distinction between patients of rapid- and slow-onset. Horm Metab Res 1999; 31: 311-316
22. Littorin B, Sundkvist G, Hagopian W, Landin-Olsson M, Lernmark A, Ostman J, Arnqvist HJ, Blohme G, Bolinder J, Eriksson JW, Lithner F, Schersten B, Wibell L. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 1999; 22: 409-412
23. Falorni A, Gambelunghe G, Forini F, Kassi G, Cosentino A, Candeloro P, Bolli GB, Brunetti P, Calcinaro F. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 309-316
24. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R, Winnock F, ver Elst K, Weets I, Kaufman L, Pipeleers DG, Rottiers R. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000; 23: 1072-1078
25. Chiu KC, Lee NP, Cohan P, Chuang LM. Beta cell function declines with age in glucose tolerant Caucasians. Clin Endocrinol 2000; 53: 569-575
26. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998; 15: 844-850
27. Skyler JS, Rabinovitch A. Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J Diabetes Complications 1992; 6: 77-88
28. BDi Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adults): definition, characterization, and potential prevention. Diabetes Care 20001; 24: 1460-1467
29. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45: 622-626
30. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, Tanaka S, Yokoyama J. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (Type 1) diabetes mellitus. Ann N Y Acad Sci 2002; 958: 117-130
31. Li X, Zhou ZG, Huang G, Peng J, Yang L, Wang JP, Yang L. Rosiglitazone combined with insulin preserves Islet β Cell Function in LADA: A preliminary study. Zhongguo Tangniaobing Zazhi 2003; 11: 242-246